CELL INTELLIGENCE · 肿瘤细胞治疗研究

移植后淋巴增殖性疾病中的免疫抑制性肿瘤微环境：发病机制与新型治疗前沿

The immunosuppressive tumor microenvironment in post-transplant lymphoproliferative disorder: pathogenesis and novel therapeutic frontiers.

黑色素瘤治疗的演变：从历史视角到未来方向

The Emerging Melanoma Management: Historical Perspective to Future Directions.

缺氧促进 BCMA 丢失与抑制性分泌组从而阻碍多发性骨髓瘤的 CAR-T 细胞治疗

Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma.

本研究表明，缺氧会降低 BCMA 表达并增强包括 sEVs 在内的免疫抑制因子的分泌，从而限制 BCMA CAR-T 细胞疗法在多发性骨髓瘤中的疗效。

从 CAR-T 细胞到外泌体免疫治疗：探索无细胞靶向肿瘤治疗的前沿

From CAR-T Cells to Exosome-Based Immunotherapy: Exploring the Frontiers of Cell-Free Targeted Cancer Therapeutics.

CAR-T 免疫疗法与新兴技术的交叉

The intersection of CAR-T immunotherapy with emerging technologies.

CAR-T 细胞来源细胞外囊泡（CAR-EVs）在肿瘤治疗中的临床潜力：一种无细胞策略

Clinical potential of CAR T cell-derived extracellular vesicles (CAR-EVs) in cancer therapy: a cell-free approach.

嵌合抗原受体细胞治疗：现状及其在衰老和阿尔茨海默病中的潜力

Chimeric Antigen Receptor Cell Therapy: Current Status and Its Potential in Aging and Alzheimer's Disease.

淋巴瘤来源细胞外囊泡抑制 CAR-T 细胞功能

Lymphoma-derived extracellular vesicles inhibit CAR T cell function.

CD19.CAR-T 细胞来源的细胞外囊泡表达 CAR 并杀伤白血病细胞，参与抗肿瘤治疗

CD19.CAR T-cell-derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy.

核散斑蛋白 SRRM2 暴露于癌细胞表面

The Nuclear Speckles Protein SRRM2 Is Exposed on the Surface of Cancer Cells.